Multidrug-resistant tuberculosis (MDR-TB) poses a major challenge in the Central African Republic (CAR), as the high incidence of tuberculosis and resistance rates to anti-tuberculosis drugs compromise efforts to manage MDR/RR-TB patients. This study evaluates the efficacy of bedaquiline, integrated into the short BPaLM regimen (Bedaquiline-Pretomanid-Linezolid-Moxifloxacin), in 68 patients with MDR-TB or pre-extensively drug-resistant (pre-XDR) TB. Strains from the National Reference Laboratory of Bangui underwent whole-genome sequencing and in silico resistance analysis. Among the participants (mean age: 32 years; 60.29% male), 82.35% had MDR-TB and 4.42% had pre-XDR TB. All strains were sensitive to bedaquiline, with no mutation detected in the atpC gene. Of the 59 patients treated, 57 (96.6%) successfully completed the 9-month protocol, confirmed by a negative culture at month 21. Two deaths, occurring before the start of treatment (due to a drug stockout), were not attributable to the treatment regimen. These results demonstrate exceptional efficacy of bedaquiline in a real-world setting, with a 100% therapeutic success rate among patients who received the treatment. The study underscores the importance of continuous access to medications and supports adopting the BPaLM regimen in CAR to improve MDR/RR-TB management. These findings support the integration of bedaquiline into national strategies, aligned with WHO objectives for tuberculosis elimination.
References
[1]
Nicolet, G., Rochat, T. and Zellweger, J. (2003) Traitement de la tuberculose. ForumMédicalSuisse-SwissMedicalForum, 506-516.
[2]
Sabeel, S.M.A., Salih, M.A., Ali, M., EL-Zaki, S., Abuzeid, N., Elgadi, Z.A.M., et al. (2017) Phenotypic and Genotypic Analysis of Multidrug-Resistant Mycobacteriumtuberculosis Isolates from Sudanese Patients. TuberculosisResearchandTreatment, 2017, Article 8340746. https://doi.org/10.1155/2017/8340746
[3]
Bagcchi, S. (2023) WHO’S Global Tuberculosis Report 2022. TheLancetMicrobe, 4, E20. https://doi.org/10.1016/s2666-5247(22)00359-7
[4]
Farra, A., Danebera, L.V., Ngaya, G., Yambiyo, B.M., Manirakiza, A. and Mossoro-Kpinde, C.D. (2023) The Contribution of the Xpert® MTB/RIF Assay to the Surveillance of Drug-Resistant Tuberculosis in the Central African Republic. JournalofTuberculosisResearch, 11, 23-32. https://doi.org/10.4236/jtr.2023.111003
[5]
Li, Y., Sun, F. and Zhang, W. (2018) Bedaquiline and Delamanid in the Treatment of Multidrug‐Resistant Tuberculosis: Promising but Challenging. DrugDevelopmentResearch, 80, 98-105. https://doi.org/10.1002/ddr.21498
[6]
Migliori, G., Pontali, E., Sotgiu, G., Centis, R., D’Ambrosio, L., Tiberi, S., et al. (2017) Combined Use of Delamanid and Bedaquiline to Treat Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis: A Systematic Review. InternationalJournalofMolecularSciences, 18, Article 341. https://doi.org/10.3390/ijms18020341
[7]
Diacon, A.H., Pym, A., Grobusch, M.P., de los Rios, J.M., Gotuzzo, E., Vasilyeva, I., et al. (2014) Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline. NewEnglandJournalofMedicine, 371, 723-732. https://doi.org/10.1056/nejmoa1313865
[8]
Zingué, D., Hien, H., Kaboré, A., Kanyala, E., Sanou, A. and Méda, N. (2012) Avantages et limites des méthodes de décontamination des expectorations. Revued’ÉpidémiologieetdeSantéPublique, 60, S126. https://doi.org/10.1016/j.respe.2012.06.309
[9]
Verboven, L., Phelan, J., Heupink, T.H. and Van Rie, A. (2022) TBProfiler for Automated Calling of the Association with Drug Resistance of Variants in Mycobacteriumtuberculosis. PLOSONE, 17, e0279644. https://doi.org/10.1371/journal.pone.0279644
[10]
Kohl, T.A., Utpatel, C., Schleusener, V., De Filippo, M.R., Beckert, P., Cirillo, D.M., et al. (2018) MTBseq: A Comprehensive Pipeline for Whole Genome Sequence Analysis of Mycobacteriumtuberculosis Complex Isolates. PeerJ, 6, e5895. https://doi.org/10.7717/peerj.5895
[11]
Pichat, C., Couvin, D., Carret, G., Frédénucci, I., Jacomo, V., Carricajo, A., et al. (2016) Combined Genotypic, Phylogenetic, and Epidemiologic Analyses of Mycobacteriumtuberculosis Genetic Diversity in the Rhône Alpes Region, France. PLOSONE, 11, e0153580. https://doi.org/10.1371/journal.pone.0153580
[12]
Tiberi, S., Pontali, E., Tadolini, M., D’Ambrosio, L. and Migliori, G.B. (2019) Challenging MDR-TB Clinical Problems—The Case for a New Global TB Consilium Supporting the Compassionate Use of New Anti-TB Drugs. InternationalJournalofInfectiousDiseases, 80, S68-S72. https://doi.org/10.1016/j.ijid.2019.01.040
[13]
Farra, A., Manirakiza, A., Yambiyo, B.M., Zandanga, G., Lokoti, B., Berlioz-Arthaud, A., et al. (2019) Surveillance of Rifampicin Resistance with Genexpert MTB/RIF in the National Reference Laboratory for Tuberculosis at the Institut Pasteur in Bangui, 2015-2017. OpenForumInfectiousDiseases, 6, ofz075. https://doi.org/10.1093/ofid/ofz075
[14]
Dje Bi, I. and Al, E. (2025) Profil épidémiologique, bactériologique et évolutif de la tuberculose résistante à Bouaké́ de 2017 à 2023. RevueMalienneD’InfectiologieetdeMicrobiologie, 19, 25-31. https://doi.org/10.53597/remim.v19i4.2949
[15]
Mounguengui, D., Ondounda, M., Mandji Lawson, J.M., Fabre, M., Gaudong, L., Mangouka, L., et al. (2012) Tuberculose multirésistante à l’hôpital d’instruction des armées de Libreville (Gabon) à propos de 16 cas. BulletindelaSociétédePathologieExotique, 105, 1-4. https://doi.org/10.1007/s13149-011-0195-8
[16]
Patra, J., Irving, H., Maini, P., Liang, J., Patra, A., Paradkar, M., et al. (2025) Treatment Outcomes among Children and Adolescents with Extensively Drug-Resistant (XDR) and Pre-XDR Tuberculosis: Systematic Review and Meta-Analysis. PLOSGlobalPublicHealth, 5, e0003754. https://doi.org/10.1371/journal.pgph.0003754
